TCE

Scorpio Tankers Inc. Announces Updates on Fourth Quarter 2023 Daily TCE Revenues and Debt and Lease Activity

Retrieved on: 
水曜日, 12月 13, 2023
Topaz, Lease, STI, TCE, MRS, LR2, Handymax, Calendar, Petroleum jelly

Consequently, Expected Revenue Days represent the total number of days the vessel is expected to be available to earn revenue.

Key Points: 
  • Consequently, Expected Revenue Days represent the total number of days the vessel is expected to be available to earn revenue.
  • Idle days, which are days when a vessel is available to earn revenue, yet is not employed, are included in revenue days.
  • Four 2012 built MR product tankers (STI Ruby, STI Topaz, STI Garnet, and STI Onyx) that are currently financed as part of the BCFL Lease Financing (MRs).
  • The purchases are expected to occur in December 2023 and January 2024 for an aggregate amount of $29.0 million.

Nordic American Tankers Ltd (NYSE: NAT) – Report as per September 30, 2023 – The direction is up in a strong market

Retrieved on: 
水曜日, 11月 29, 2023
TCE, NAT, Ship, Suezmax, Shipbuilding

Our main customers, the major oil companies know that our ships are first class and they know they can always rely on Nordic American.

Key Points: 
  • Our main customers, the major oil companies know that our ships are first class and they know they can always rely on Nordic American.
  • Inflation in the US came in at 3.2% in October, down from 9.1% a little more than a year ago.
  • The US economy is on the right track and China is also taking steps to stimulate its economy.
  • We are scheduled to take delivery of the recently purchased suezmax tanker, to be named “Nordic Hawk”,  on December 4, 2023.

Grindrod Shipping Holdings Ltd. Announces Unaudited Financial Results for the Three Months and Nine Months Ended September 30, 2023

Retrieved on: 
火曜日, 11月 28, 2023
Nine Months, TMI, BSI, Handymax, EGM, Sale, TCE, Acquisition, Insurance, Three Months, Asset, GAAP, Cryptocurrency

Unaudited Results for the nine months ended September 30, 2023 and 2022

Key Points: 
  • Unaudited Results for the nine months ended September 30, 2023 and 2022
    Revenue was $298.3 million for the nine months ended September 30, 2023 and $379.1 million for nine months ended September 30, 2022.
  • Interest income was $1.8 million for the nine months ended September 30, 2023 and $0.8 million for the nine months ended September 30, 2022.
  • Interest expense was $13.5 million for the nine months ended September 30, 2023 and $11.8 million for the nine months ended September 30, 2022.
  • Income tax expense was $0.3 million for the nine months ended September 30, 2023 and $0.4 million for the nine months ended September 30, 2022.

Performance Shipping Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2023

Retrieved on: 
月曜日, 11月 27, 2023
Sale, TCE, Acquisition, Public expenditure, Tanker, Aframax, Shipbuilding, Share repurchase, Employment, Environment, Security (finance)

The 2023 third quarter results compared to a net income of $10.7 million and net income attributable to common stockholders of $10.4 million for the same period in 2022.

Key Points: 
  • The 2023 third quarter results compared to a net income of $10.7 million and net income attributable to common stockholders of $10.4 million for the same period in 2022.
  • Earnings per share, basic and diluted, for the third quarter of 2023 were $0.88 and $0.27, respectively.
  • Fleetwide, the average TCE rate for the third quarter of 2023 was $31,787, compared with an average rate of $34,411 for the same period in 2022.
  • Net income for the nine months ended September 30, 2023, amounted to $44.5 million, compared to a net income of $12.5 million for the nine months ended September 30, 2022.

Ten Ltd. Reports Results For the Nine Months and Third Quarter Ended September 30, 2023 and Declares Dividend Date

Retrieved on: 
火曜日, 11月 21, 2023
Policy, Sale, TCE, Health, TNP, Depreciation, Total, Series, Employment, Cryptocurrency

Net income for the first nine months of 2023 at $272 million, $166 million higher from the 2022 first nine months equating to $8.19 per common share.

Key Points: 
  • Net income for the first nine months of 2023 at $272 million, $166 million higher from the 2022 first nine months equating to $8.19 per common share.
  • Adjusted EBITDA reached $367 million compared to $236 million in the 2022 first nine-month period, a $131 million increase.
  • General and administrative expenses during the third quarter of 2023 experienced a 21% drop from the 2022 third quarter to $6.3 million in the 2023 third quarter.
  • This distribution reflects the second regular dividend payment in 2023 which is in line with TEN’s semi-annual dividend policy.

Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs

Retrieved on: 
火曜日, 12月 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Dexamethasone, ASH, CRS, Patient, Cell, Infection, Bortezomib, B-cell maturation antigen, GPRC5D, Carfilzomib, Therapy, Bristol Myers Squibb, ORR, Cancer, Diagnosis, Anemia, International Myeloma Foundation, CD3, Cytokine release syndrome, Haematopoietic system, Multiple myeloma, Immunomodulatory imide drug, Safety, Immune system, Incidence, Aes, DOR, Science, Hook effect, Public, Drug discovery, Society, Estate (law), Lenalidomide, Proteasome inhibitor, Thrombocytopenia, PFS, BMY, Daratumumab, Neutropenia, Partnership, Skin, Life, Mezi proudy, Research, NYSE, Disease, MRD, Translational Genomics Research Institute, TCE, Survival, BMS, BCMA, Biology, Pharmaceutical industry, Vaccine, Fine chemical, Cohort, RRMM

Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.
  • These data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
  • While multiple myeloma remains a relentless disease, we continue to transform the multiple myeloma treatment paradigm by dramatically improving outcomes for every patient.
  • As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
日曜日, 12月 10, 2023
Webcast, Multiple myeloma, Associate, Immunomodulatory imide drug, Safety, SAN, DNA, TSCM, Prodrug, Therapy, Gene, International, CRS, Tissue, Artificial intelligence, SCR, Cytogenetics, Patient, Conference call, Blood, Haemophilia, Conference, Graft-versus-host disease, ORR, TCE, Cancer, Transposase, Partnership, Roche, Malignancy, Antibody, Neurotoxicity, Kinetics, Haemophilia A, RRMM, Cyclophosphamide, BCMA, Physician, Investigator's brochure, Bone marrow, ITT, Vanderbilt-Ingram Cancer Center, Cytokine release syndrome, Vaccine, Pharmaceutical industry, Broadcasting, Hematology

The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).
  • We are excited to have taken this first step with our early P-BCMA-ALLO1 clinical results.
  • They inspire us to further develop P-BCMA-ALLO1 in partnership with Roche, and to continue advancing our entire allogeneic TSCM cell-based CAR-T portfolio."
  • Title: Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Session Title: 704.

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
火曜日, 11月 7, 2023
FDA, Research, TCE, NSCLC, Therapy, NACLC, Head, G&A, Conference, PD-1, ROR2, R, Conditional, CAB, KOL, FPI, Nivolumab, Webcast, Interim, SAN, Lung cancer, Melanoma, Cancer, TMP, AXL, EGFR, Pharmaceutical industry, Rail transport, Medical imaging, Audit, Cryptocurrency, Patient

“At BioAtla, our highest priority is to deliver innovative, life-changing therapies to cancer patients with significant unmet medical needs.

Key Points: 
  • “At BioAtla, our highest priority is to deliver innovative, life-changing therapies to cancer patients with significant unmet medical needs.
  • Research and development (R&D) expenses were $28.4 million for the quarter ended September 30, 2023 compared to $19.8 million for the same quarter in 2022.
  • General and administrative (G&A) expenses were $6.6 million for the quarter ended September 30, 2023 compared to $6.3 million for the same quarter in 2022.
  • Net loss for the third quarter ended September 30, 2023 was $33.3 million compared to a net loss of $25.8 million for the same quarter in 2022.

International Seaways Reports Third Quarter 2023 Results

Retrieved on: 
火曜日, 11月 7, 2023
Maritime, Energy, Transport, Oil, Gas, Line of credit, Sale, TCE, NYSE, International, EBITDA, Share repurchase, Exercise, VLCC, Revolver, Credit, Depreciation, INSW, Aframax, Access code, Reinsurance, Bookkeeping, Security (finance), Satellite navigation device, Self storage, Bank, Holding company, Natural gas, Airline, Renting, Video game, Beauty salon, Suezmax, LNG, Sound (geography)

International Seaways, Inc. (NYSE: INSW) (the “Company”, “Seaways”, or “INSW”), one of the largest tanker companies worldwide providing energy transportation services for crude oil and petroleum products, today reported results for the third quarter 2023.

Key Points: 
  • International Seaways, Inc. (NYSE: INSW) (the “Company”, “Seaways”, or “INSW”), one of the largest tanker companies worldwide providing energy transportation services for crude oil and petroleum products, today reported results for the third quarter 2023.
  • “We continued to generate significant cash and earnings from our diversified portfolio of crude and product tankers during the third quarter,” said Lois K. Zabrocky, International Seaways’ President and CEO.
  • Shipping revenues for the Crude Tankers segment were $114.3 million for the third quarter of 2023, compared to $77.1 million for the third quarter of 2022.
  • The Company will host a conference call to discuss its third quarter 2023 results at 9:00 a.m. Eastern Time (“ET”) on Tuesday, November 7, 2023.

Ardmore Shipping Corporation Announces Financial Results For The Three and Nine Months Ended September 30, 2023

Retrieved on: 
火曜日, 11月 7, 2023
Risk, Instability, TCE, Policy, ASC, NYSE, Chemical substance, Three Months, IMO, Conversation, Financial result, Carbon, GAAP, Nature, Commercial, Analysis, Depreciation, Attack, Annual report, Administration, State Administrative Expenses, Clothing, Holding company, Construction, Fuel oil, Beauty salon, Cryptocurrency, Life insurance, Airline, Adjustment

HAMILTON, Bermuda, Nov. 7, 2023 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and nine months ended September 30, 2023.

Key Points: 
  • HAMILTON, Bermuda, Nov. 7, 2023 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and nine months ended September 30, 2023.
  • MR tankers earned an average spot TCE rate of $28,493 per day for the three months ended September 30, 2023.
  • Chemical tankers earned an average TCE rate of $20,023 per day for the three months ended September 30, 2023.
  • Vessel operating expenses were $14.4 million for the three months ended September 30, 2023, an increase of $1.1 million from $13.3 million for the three months ended September 30, 2022.